

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70254 A1

(51) International Patent Classification⁷: A61K 38/17,
A61P 3/04, 3/10, 5/48, C07K 14/705

(21) International Application Number: PCT/GB01/01211

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0006864.3 21 March 2000 (21.03.2000) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAIRNS, William,
John [GB/GB]; GlaxoSmithKline, New Frontiers Science
Park South, Third Avenue, Harlow, Essex CM19 5AW
(GB). HOLDER, Julie, Caroline [GB/GB]; Glaxo-
SmithKline, New Frontiers Science Park South, Third
Avenue, Harlow, Essex CM19 5AW (GB). PATEL, Lisa
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: CONNELL, Anthony, Christopher; Corporate
Intellectual Property, SmithKline Beecham, Two New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:
27 December 2001

(15) Information about Correction:
see PCT Gazette No. 52/2001 of 27 December 2001, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/70254 A1

(54) Title: USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

(57) Abstract: The use of NOT1 or NOT1 a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions.

AN

USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

Field of the Invention

This invention relates to new uses for polynucleotides and polypeptides encoded by them, to their use in therapy and in identifying compounds which may be agonists which are potentially useful in therapy.

5

Summary of the Invention

In one aspect, the invention relates to new uses of the orphan nuclear receptor, NOT1 or its splice variant NOT1a polynucleotides and polypeptides. Such uses include the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, hereinafter referred to as "the Diseases", amongst others. In another aspect the invention relates to methods for identifying compounds which activate NOT1 or NOT1a polypeptides, for example agonists, using NOT1 or NOT1a materials, and treating conditions associated with NOT1 or NOT1a imbalance with the identified agonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NOT1 or NOT1a activity or levels.

15

Description of the Invention

In a first aspect, the present invention relates to the use of a compound selected from:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a compound which activates a NOT1 or NOT1a polypeptide; or
- (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,

20

for the manufacture of a medicament for treating:

- (i) obesity;
- (ii) insulin resistance;
- (iii) type 2 diabetes;
- (iv) impaired glucose tolerance;
- (v) cachexia; or
- (vi) liposarcoma.

25

Such NOT1 polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

30

Further polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

NOT1a polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include those comprising the amino acid of SEQ ID NO:4

Further NOT1a polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include the polypeptide of SEQ ID NO:4. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The NOT1 and NOT1a polypeptides relating to the present invention also include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

NOT1 and NOT1a polypeptides relating to the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to NOT1 or NOT1a polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID

NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:3 encoding the polypeptides of SEQ ID NO:2 and SEQ ID NO:4 respectively.

Further polynucleotides relating to the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:4, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:3 over the entire length of SEQ ID NO:1 or SEQ ID NO:3 respectively. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 as well as the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.

The invention also relates to polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of a human NOT1 cDNA is given in SEQ ID NO:1 (from Mages, H.W. et al. Mol. Endocrinol. 1994; 4(11): 1583-1591, EMBL: X75918). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 318 to 3115) encoding a polypeptide of 598 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The nucleotide sequence of the splice variant NOT1a is given in SEQ ID NO:3 (from Patent Application WO00/77202; SmithKline Beecham) and is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1368) encoding a polypeptide of 455 amino acids, the polypeptide of SEQ ID NO:4, representing a splice variant of NOT1. The nucleotide sequence encoding the polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:3 or it may be a

sequence other than the one contained in SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

The gene encoding the NOT1 polypeptide of SEQ ID NO:2 has been localised to human chromosome 2q22-2q23..

5 Preferred polypeptides and polynucleotides are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one NOT1 or NOT1a activity, which may include antigenic activity.

10 NOT1 and NOT1a polynucleotides may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Such polynucleotides can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When NOT1 or NOT1a polynucleotides are used for the recombinant production of NOT1 or NOT1a polypeptides, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence, or other fusion peptide portions. For example, a marker sequence which
20 facilitates purification of the fused polypeptide can be encoded, for example a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25 Recombinant NOT1 or NOT1a polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from NOT1 or NOT1a DNA constructs.

30 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for NOT1 or NOT1a polynucleotides. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate

transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect
5 cells such as *Drosophila* S2 and *Spodoptera* S9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK and HEK 293.

The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be
10 incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is
15 recovered.

NOT1 or NOT1a polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography
20 and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of
25 SEQ ID NO:1 or SEQ ID NO:3 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression or otherwise altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood,
30 urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled NOT1 or NOT1a nucleotide

sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242).

5 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising NOT1 or NOT1a nucleotide sequence or fragments thereof can be constructed to

10 conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the NOT1 gene by the methods described. In addition,

15 such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased level of polypeptide or mRNA. Decreased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can

20 be used to determine levels of a NOT1 or NOT1a protein in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

(a) a NOT1 or NOT1a polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1 or

25 SEQ ID NO:3, or fragments thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a NOT1 or NOT1a polypeptide, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof; or

(d) an antibody to a NOT1 or NOT1a polypeptide, preferably to the polypeptide of SEQ ID NO:2

30 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, amongst others.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides
5 in the prior art.

Antibodies generated against NOT1 or NOT1a polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used.
10 Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.
15

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a NOT1 or NOT1a polypeptide, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening,
20 diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.
25

In a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate the function of NOT1 or NOT1a polypeptides. In general, agonists
30 may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the

polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

5 The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Further, the screening methods may simply comprise the steps of mixing a
10 candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring NOT1 or NOT1a activity in the mixture, and comparing the NOT1 or NOT1a activity of the mixture to a standard.

NOT1 or NOT1a polynucleotides, polypeptides and antibodies to the polypeptide as hereinabove described may also be used to configure screening methods for detecting the effect
15 of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may enhance the production of polypeptide, for example agonists, from suitably manipulated cells or tissues.

20 The NOT1 or NOT1a polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated
25 with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists of NOT1 or NOT1a polypeptides which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

30 Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which enhance the production of such polypeptides, which comprises:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a recombinant cell expressing a NOT1 or NOT1a polypeptide;

(c) a cell membrane expressing a NOT1 or NOT1a polypeptide; or

(d) antibody to a NOT1 or NOT1a polypeptide;

which NOT1 or NOT1a polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:4.

5 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist of the NOT1 or NOT1a polypeptide, by:

10 (a) determining in the first instance the three-dimensional structure of the NOT1 or NOT1a polypeptide;

(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist;

(c) synthesising candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

15 (d) testing whether the candidate compounds are indeed agonists.

It will be further appreciated that this will normally be an iterative process.

- In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia, or liposarcoma, related to an under-expression of, NOT1 or NOT1a polypeptide activity.

20 For treating abnormal conditions related to an under-expression of NOT1 or NOT1a polypeptides and their activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene
25 therapy may be employed to effect the endogenous production of NOT1 or NOT1a by the relevant cells in the subject. For example, a NOT1 or NOT1a polynucleotide may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a NOT1 or NOT1a polypeptide such that the packaging
30 cell now produces infectious viral particles containing the NOT1 or NOT1a gene. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the NOT1 or NOT1a polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another

approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a NOT1 or NOT1a polypeptide, such as the soluble form of a NOT1 or NOT1a polypeptide, agonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. NOT1 or NOT1a polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a NOT1 or NOT1a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

NOT1 or NOT1a polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a NOT1 or NOT1a polynucleotide, such as a DNA or RNA, to encode a NOT1 or NOT1a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

“Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

“Isolated” means altered “by the hand of man” from the natural state. If an “isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.

“Polynucleotide” generally refers to any polyribonucleotide or polydeoxynucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

“Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.

“Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.

“Polypeptide” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

“Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking,

10 cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for

15 instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis:

20 Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a

25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many

30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.

5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, 10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity 15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

- 25 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)
 Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)
 Gap Penalty: 12
 Gap Length Penalty: 4

30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the
 5 default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1 or SEQ ID NO:3, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide
 10 deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of
 15 nucleotides in SEQ ID NO:1 or SEQ ID NO:3 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1 or SEQ ID NO:3, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ
 20 ID NO:1 or SEQ ID NO:3, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the
 25 polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2 or SEQ ID NO:4, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group
 30 consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of

amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, or:

5

$$n_a \leq x_a - (x_a \cdot y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

10

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

15

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

20

25

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Examples

Example 1 - Analysis of NOT1 and NOT1a expression in human tissues

5
10
15
Generation of samples for TaqMan mRNA analysis: Human tissue or RNA was purchased (Biochain, San Leandro, CA; Invitrogen, Leek, The Netherlands; Clontech, Palo Alto, CA) or donated (Netherlands Brain Bank, Amsterdam, the Netherlands) and poly A+ RNA was prepared by the PolyA Tract method according to manufacturers instructions (Promega, USA). The poly A+ RNA samples from 20 body tissues and 19 brain-regions from 4 individuals per tissue (two males/two females) were quantitated using OD260nm measurement or the RiboGreen fluorescent method (Molecular Probes, Oregon, USA) and 1ug of each RNA was reverse transcribed using random nonomers and Superscript II reverse transcriptase according to manufacturers instructions (Life Technologies). The cDNA prepared was diluted to produce up to 1,000 replicate 96-well plates using Biomek robotics (Beckman Coulter, High Wycombe, UK), so that each of the wells contained the cDNA produced from 1ng RNA for the appropriate tissue. The 96-well plates were stored at -80°C prior to use.

20
25
30
TaqMan PCR: This was performed following the procedure published by Sarau H.M. et al, ("Identification, Molecular Cloning, Expression and Characterisation of a Cysteinyl Leukotriene Receptor", Molecular Pharmacology, 1999, 56, 657-663.) TaqMan quantitative PCR was conducted to measure either NOT-1 or NOT1a using replicate 96-well plates. A 20ul volume of a PCR master mix (containing 2.5ul TaqMan buffer, 6ul 25mM MgCl₂, 0.5ul of 10mM dATP, 0.5ul of 20mM dUTP, 0.5ul of 10mM dCTP, 0.5ul of 10mM dGTP, 0.25ul Uracil-N-glycosylase, 1ul of 10uM forward primer, 1ul of 10uM reverse primer, 0.5ul 5uM TaqMan probe, 0.125ul TaqGold [PE Biosystems], 6.625ul water) was added to each well using Biomek robotics (Beckman Coulter, High Wycombe, UK), and the plate capped using optical caps (PE Biosystems). The PCR reaction was carried out on an ABI7700 Sequence Detector (PE Biosystems) using the PCR parameters: 50°C for 2 minutes, 95°C for 10 minutes and 45 cycles of 94°C for 15 seconds, 60°C for 1 minute, and the level of mRNA-derived cDNA in each sample was calculated from the TaqMan signal using plasmid/genomic DNA calibration standards included in each run. The level of genomic DNA contaminating the original RNA samples was shown to be negligible (<10 copies genomic DNA/ng RNA) by TaqMan measurement of genomic sequence for ten genes in replicate samples taken through the reverse transcription

procedure described with the omission of reverse transcriptase. Gene-specific reagents for NOT-1:

forward primer: 5'-CCGCCAGCAATAATTGACAA-3',

reverse primer: 5'-TTCCATTATCATTCCAGTTCCTTTG-3',

5 TaqMan probe: 5'-CACTTTACCTTTCTAAGACCTCCTCCCAAGCA-3';

and for NOT1a:

forward primer: 5'-TCCTTCGATTAGCATACAGAATA-3',

reverse primer: 5'-CCCGTGTCTCTCTGTGACCAT-3',

TaqMan probe: 5'-TCTGCCTTCTCCTGCATTGCTGCC-3'.

10

Results

The results are shown in Table 1. Analysis of expression of both NOT1 and NOT1a mRNA by TaqMan showed relatively widespread distribution. However, the expression levels found in adipose tissue were significantly higher than for those found in any other tissue. Levels of expression are scored from +++++ to -, with +++++ representing the highest expression levels. +/- indicates weakly detectable expression.

Table 1

		NOT1	NOT1a
20	Brain	++	+
	Pituitary	+++	++
	Heart	+	+/-
	Lung	+	+/-
	Liver	+	+
25	Foetal Liver	+	+/-
	Kidney	+	+
	Skeletal Muscle	++	++
	Stomach	+	+
	Intestine	+	+
30	Spleen	+	+
	Lymphocytes	++	++
	Macrophage	-	-
	Adipose	+++++	+++++
	Pancreas	+	+
35	Prostate	++	+

Placenta	+	+
Cartilage	+	+
Bone	-	-
Bone Marrow	+/-	+/-

5

Example 2 - Analysis of NOT1 expression in 3T3 cells

Insulin and dexamethasone induced differentiation of 3T3-L1 cells is an established in vitro model for adipogenesis. Levels of NOT1 mRNA were quantified in this model. The 3T3-L1 fibroblast cell line was obtained from the American Type Culture Collection. Cells were grown to confluence in Dulbeccos modified Eagles Medium containing 10% FCS. Differentiation was undertaken with in Dulbeccos modified Eagles Medium containing 10% FCS supplemented with 0.5mM isobutyl methyl xanthine, 0.25uM dexamethasone and insulin (5ug/ml) for 48 hours followed by Dulbeccos modified Eagles Medium containing 10% FCS supplemented with insulin (5ug/ml) for a further 48 hours. Cells were grown in Dulbeccos modified Eagles Medium containing 10% FCS for the remainder of the culture period.

On each day of experimentation the cell media was removed by aspiration and the cell monolayer extracted with 1ml of Trizol. RNA was prepared according to the manufacturer's instructions. Quantification of mRNA transcripts was carried out using the Taqman 5' nuclease assay as previously described (Wang T & Brown MJ (1999) Anal. Biochem. 269 p198-201). Total RNA was treated with DNaseI (Gibco BRL) and reverse transcribed using random hexamers (Stratagene) and Superscript II reverse transcriptase (Gibco BRL). Transcript cDNA levels were then measured using Taqman assay primers and fluorogenic probes as described in example 1. The results are shown in Table 2. In Table 2, T1 refers to day 1, T2 to day 2 etc. and the figures in the right hand column indicate relative levels of Not1 mRNA, the figure on day 1 being 100%.

Table 2

T1	100
T2	139
T3	57
T4	2.8
T5	3.7
T6	0.9
T7	3.9
T8	8.7
T9	0.6
T10	n.d.
T11	3.4
T12	8.5

The results show that NOT1 expression is downregulated upon differentiation of 3T3-L1 cells, an established in vitro model for adipogenesis. This finding is consistent with NOT1 having a
5 function in maintaining the undifferentiated pre-adipocyte state.

Claims

1. The use of a compound selected from:
 - (a) a NOT1 or NOT1a polypeptide;
 - (b) a compound which activates a NOT1 or NOT1a polypeptide; or
 - (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,for the manufacture of a medicament for treating:
 - (i) obesity;
 - (ii) insulin resistance;
 - (iii) type 2 diabetes;
 - (iv) impaired glucose tolerance;
 - (v) cachexia; or
 - (vi) liposarcoma.
2. The use according to claim 1 wherein the medicament is used to treat obesity.
3. The use according to claim 1 wherein the medicament is used in the treatment of insulin resistance.
4. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 95% identity to the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
5. The use according to claim 4 wherein the isolated polypeptide is the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
6. The use according to claim 1 wherein the medicament comprises a compound which activates a NOT or NOT1a polypeptide.
7. The use according to claim 1 wherein the medicament comprises a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
8. The use according to claim 7 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
9. The use according to claim 7 or 8 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

SEQUENCE LISTING

<110> SmithKline Beecham plc

<120> New Use

<130> P32537.

<160> 4

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 3427

<212> DNA

<213> Homo sapiens

<400> 1

gctcgcgcac ggctccgcgg tcccttttgc ctgtccagcc ggccgcctgt ccttgetccc	60
tccctccgtg agtgtccggg ttcccttcgc ccagctctcc caccctacc cgaccccggc	120
gcccgggctc ccagagggaa ctgcacttcg gcagagttga atgaatgaag agagacgcgg	180
agaactccta aggaggagat tggacaggct ggactcccca ttgcttttct aaaaatcttg	240
gaaactttgt ccttcattga attacgacac tgtccacctt taatttcctc gaaaacgcct	300
gtaactcggc tgaagccatg ccttgtgttc aggcgcagta tgggtcctcg cctcaaggag	360
ccagccccgc ttctcagagc tacagttacc actcttcggg agaatacagc tccgatttct	420
taactccaga gtttgtcaag tttagcatgg acctcaccaa cactgaaatc actgccacca	480
cttctctccc cagcttcagt acctttatgg acaactacag cacaggctac gacgtcaagc	540
caccttgctt gtaccaaatg cccctgtccg gacagcagtc ctccattaag gtagaagaca	600
ttcagatgca caactaccag caacacagcc acctgcccc ccagtctgag gagatgatgc	660
cgcactccgg gtcggtttac tacaagccct cctcgcctcc gacgcccacc accccgggct	720
tccagggtgca gcacagcccc atgtgggacg acccgggac tctccacaac ttccaccaga	780
actacgtggc cactacgcac atgatcgagc agaggaaaac gccagtctcc cgcctctccc	840
tcttctcctt taagcaatcg cccctgggca ccccggtgtc tagttgccag atgcgcttcg	900
acgggccccct gcacgtcccc atgaaccggg agcccgccgg cagccaccac gtgggtggacg	960
ggcagacctt cgctgtgccc aaccccatc gcaagcccgc gtccatgggc tccccgggccc	1020
tgcatatcgg ccacgcgtct cagctgctcg acacgcaggt gccctcaccg ccgtcgcggg	1080
gtccccctc caacgagggg ctgtgcgctg tgtgtgggga caacgcggcc tgccaacact	1140
acggcgctgcg cacctgtgag ggctgcaaa gcttctttaa gcgcacagtg caaaaaaatg	1200

```

caaaatacgt gtgttttagca aataaaaaact gcccagtgga caagcgtcgc cggaatcgct 1260
gtcagtactg ccgatttcag aagtgcctgg ctgttgggat ggtcaaagaa gtggttcgca 1320
cagacagttt aaaaggccgg agaggctcgtt tgccctcgaa accgaagagc ccacaggagc 1380
cctctcccc ttcgcccccg gtgagtctga tcagtgcctt cgtcagggcc catgtcgact 1440
ccaacccggc tatgaccagc ctggactatt ccagggtcca ggccaacctt gactatcaaa 1500
tgagtggaga tgacaccagc catatccagc aattctatga tctcctgact ggctccatgg 1560
agatcatccg gggctgggca gagaagatcc ctggcttcgc agacctgccc aaagccgacc 1620
aagacctgct ttttgaatca gctttcttag aactgtttgt ccttcgatta gcatacaggt 1680
ccaacccagt ggagggtaaa ctcattctttt gcaatggggt ggtcttgca cagggtgcaat 1740
gcgttcgtgg ctttggggaa tggattgatt ccattgttga attctcctcc aacttgacaga 1800
atatgaacat cgacatttct gccttctcct gcattgctgc cctggctatg gtcacagaga 1860
gacacgggct caaggaaccc aagagagtgg aagaactgca aaacaagatt gtaaattgtc 1920
tcaaagacca cgtgactttc aacaatgggg ggttgaaccg cccaattat ttgtccaaac 1980
tgttggggaa gtcccagaa cttcgtaccc ttgacacaca ggggctacag cgcattttct 2040
acctgaaatt ggaagacttg gtgccaccgc cagcaataat tgacaaactt ttcctggaca 2100
ctttacctt ctaagacctc ctcccaagca cttcaaagga actggaatga taatggaaac 2160
tgtcaagagg gggcaagtca catgggcaga gatagccgtg tgagcagttc cagctcaagc 2220
tgcccccat ttctgtaacc ctctagccc ccttgatccc taaagaaaac aaacaaacaa 2280
acaaaaactg ttgctatttc ctaacctgca ggcagaacct gaaagggcat ttgggtccg 2340
gggcatcctg gat tttagaac atggactaca cacaatacag tggataaac tttttattct 2400
cagtttaaaa atcagtttgt tttcagaag aaagattgct ataaggtata atgggaaatg 2460
tttggccatg cttggttgtt gcagttcaga caaatgtaac acacacacac atacacacac 2520
acacacacac agagacacat cttaggggga cccacaagta ttgcccttta acaagacttc 2580
aaagttttct gctgtaaaga aagctgtaat atatagtaaa actaaatggt gcgtgggtgg 2640
catgagttga agaaggcaaa ggcttgtaaa ttaccacat gcagtttggc tttttaaatt 2700
at ttgtgccc tttttatgaa taaatattac aaattctaaa agataagtgt gtttgcaaaa 2760
aaaaagaaaa taaatacata aaaaagggac aagcatgttg attctagggt gaaaatgtta 2820
taggcacttg ctacttcagt aatgtctata ttatataaat agtatttcag acactatgta 2880
gtctgttaga ttttataaag attggtagtt atctgagctt aaacattttc tcaattgtaa 2940
aatagggtgg cacaagtatt acacatcaga aaatcctgac aaaagggaca catagtgttt 3000
gtaacaccgt ccaacattcc ttgtttgtaa gtgttgatg taccgttgat gttgataaaa 3060
agaaagttta tatcttgatt atttgttgt cttaaagctaa acaaaaactg catgcagcag 3120
cttttgactg tttccagagt gcttataata tacataactc cctggaaata actgagcact 3180
ttgaattttt tttatgtcta aaattgtcag ttaatttatt atttgtttg agtaagaatt 3240
ttaatatgac catattctgt agtatttttc ttgtatatatt tctagtatgg cacatgatat 3300
gagtcactgc ctttttttct atgggtgatg acagttagag atgctgattt tttttctgat 3360
aaattctttc tttgagaaag acaattttta tgtttacaac aataaacat gtaaataaaa 3420
aaaaaaa 3427

```

<210> 2

<211> 598

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser
 1           5           10           15
Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser
      20           25           30
Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn
      35           40           45
Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met
      50           55           60
Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln
65           70           75           80
Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln
      85           90           95
Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu
      100          105          110
Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro
      115          120          125
Thr Pro Thr Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp
      130          135          140
Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr
      145          150          155          160
His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe
      165          170          175
Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met
      180          185          190
Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly
      195          200          205
Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile
      210          215          220
Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala
      225          230          235          240
Ser Gln Leu Leu Asp Thr Gln Val Pro Ser Pro Pro Ser Arg Gly Ser
      245          250          255
Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys
      260          265          270
Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys

```

275 280 285
 Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn
 290 295 300
 Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe
 305 310 315 320
 Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp
 325 330 335
 Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro
 340 345 350
 Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu
 355 360 365
 Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr
 370 375 380
 Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr
 385 390 395 400
 Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile
 405 410 415
 Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys
 420 425 430
 Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val
 435 440 445
 Leu Arg Leu Ala Tyr Arg Ser Asn Pro Val Glu Gly Lys Leu Ile Phe
 450 455 460
 Cys Asn Gly Val Val Leu His Arg Leu Gln Cys Val Arg Gly Phe Gly
 465 470 475 480
 Glu Trp Ile Asp Ser Ile Val Glu Phe Ser Ser Asn Leu Gln Asn Met
 485 490 495
 Asn Ile Asp Ile Ser Ala Phe Ser Cys Ile Ala Ala Leu Ala Met Val
 500 505 510
 Thr Glu Arg His Gly Leu Lys Glu Pro Lys Arg Val Glu Glu Leu Gln
 515 520 525
 Asn Lys Ile Val Asn Cys Leu Lys Asp His Val Thr Phe Asn Asn Gly
 530 535 540
 Gly Leu Asn Arg Pro Asn Tyr Leu Ser Lys Leu Leu Gly Lys Leu Pro
 545 550 555 560
 Glu Leu Arg Thr Leu Cys Thr Gln Gly Leu Gln Arg Ile Phe Tyr Leu
 565 570 575
 Lys Leu Glu Asp Leu Val Pro Pro Pro Ala Ile Ile Asp Lys Leu Phe
 580 585 590
 Leu Asp Thr Leu Pro Phe

595

<210> 3

<211> 1676

<212> DNA

<213> Homo sapiens

<400> 3

atgccttg	ttcaggcg	catatgggt	tcgcctcaag	gagccagccc	cgctttctcag	60
agctacag	ttaccactcttc	gggagaatac	agctccgatt	tcttaactcc	agagtttgtc	120
aagtttag	catggacctcac	caacactgaa	atcactgcc	ccactttctct	ccccagcttc	180
agtacctt	ttaggacaacta	cagcacaggc	tacgacgtca	agccaccttg	cttgtaacaa	240
atgcccct	gtccggacagca	gtcctccatt	aaggtagaag	acattcagat	gcacaactac	300
cagcaacac	a gccacctgcc	cccccagctc	gaggagatga	tgccgcactc	cggttcggtt	360
tactacaag	cctcctcgcc	cccgacgccc	accaccccg	gcttcaggt	gcagcacagc	420
cccatgtg	ggg acgacccggg	atctctccac	aacttccacc	agaactacgt	ggccactacg	480
cacatgat	cagcagaggaa	aaagccagtc	tcccgcctct	ccctcttctc	ctttaagcaa	540
tcgccccct	gacccccggt	gtctagtgtc	cagatgcgct	tcgacggggc	cctgcacgtc	600
cccatgaac	cggagcccg	cggcagccac	cacgtggtg	acgggcagac	cttcgctgtg	660
cccaacccc	a ttcgcaagcc	cgcgtccatg	ggcttcccg	gcctgcagat	cggccacgcg	720
tctcagct	gcgcacgcga	ggtgccctca	ccgccgtcgc	ggggctcccc	ctccaacgag	780
gggctgtg	cgtgtgtgtg	ggacaacgcg	gcctgccaac	actacggcgt	gcgcacctgt	840
gagggtgc	aaggcttctt	taagcgcaca	gtgcaaaaaa	atgcaaaata	cgtgtgttta	900
gcaataaaa	actgcccagt	ggacaagcgt	cgcgggaatc	gctgtcagta	ctgccgattt	960
cagaagtgc	tggctgttgg	gatggtcaaa	gaagtgggtc	gcacagacag	tttaaaaggc	1020
cggagaggt	cgtttgccctc	gaaaccgaag	agcccacagg	agccctctcc	cccttcgccc	1080
ccggtgag	tcgatcagtc	cctcgtcagg	gcccattgtc	actccaaccc	ggctatgacc	1140
agcctgg	acttccaggtt	ccaggcgaac	cctgactatc	aatgagtg	agatgacacc	1200
cagcatat	ccagcaattcta	tgatctctc	actggctcca	tggagatcat	ccggggctgg	1260
gcagaga	aga tccctggctt	cgcagacctg	cccaaagccg	accaagacct	gctttttgaa	1320
tcagcttt	ctctagaactgtt	tgtccttcga	ttagcataca	gaatatgaac	atcgacattt	1380
ctgccttt	ctcctgtgct	gccctggcta	tggtcacaga	gagacacggg	ctcaaggaac	1440
ccaagaga	gt ggaagaactg	caaaacaaga	ttgtaaattg	tctcaaagac	cacgtgactt	1500
tcaacaat	ggggttgaac	cgccccaatt	atttgtccaa	actgttggg	aagctccag	1560
aacttcgt	ac ctttgcaca	caggggttac	agcgcatttt	ctacctgaaa	ttggaagact	1620
tggtgcc	cacc gccagcaata	attgacaaac	tttctctgga	cactttacct	ttctaa	1676

<210> 4

<211> 455

<212> PRT

<213> Homo sapiens

<400> 4

```

Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser
 1             5             10             15
Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser
      20             25             30
Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn
      35             40             45
Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met
      50             55             60
Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln
      65             70             75             80
Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln
      85             90             95
Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu
      100            105            110
Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro
      115            120            125
Thr Pro Thr Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp
      130            135            140
Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr
      145            150            155            160
His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe
      165            170            175
Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met
      180            185            190
Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly
      195            200            205
Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile
      210            215            220
Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala
      225            230            235            240
Ser Gln Leu Leu Asp Thr Gln Val Pro Ser Pro Pro Ser Arg Gly Ser
      245            250            255
Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys
      260            265            270
Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys
      275            280            285
Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn

```

290		295		300
Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe				
305		310		315 320
Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp				
	325		330	335
Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro				
	340		345	350
Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu				
	355		360	365
Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr				
	370		375	380
Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr				
385		390		395 400
Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile				
	405		410	415
Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys				
	420		425	430
Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val				
	435		440	445
Leu Arg Leu Ala Tyr Arg Ile				
450		455		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/01211

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 A61P3/04 A61P3/10 A61P5/48 C07K14/705		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)	
A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NURR1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295 <div style="text-align: center;">-/--</div>	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search 11 July 2001		Date of mailing of the international search report 27/07/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Blanco Urgoiti, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01211

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARUYAMA K ET AL: "THE NGFI-B SUBFAMILY OF THE NUCLEAR RECEPTOR SUPERFAMILY (REVIEW)" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY, GR, vol. 12, no. 6, 23 March 1998 (1998-03-23), pages 1237-1243, XP000946431 ISSN: 1019-6439	
A	ISHIHARA NORIKO ET AL: "Signal transduction pathways leading to the NOR-1 gene induction in MCF-7 breast cancer cells." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1047 XP002171751 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638	
A	MAMOUNAS M ET AL: "ANALYSIS OF THE GENES INVOLVED IN THE INSULIN TRANSMEMBRANE MITOGENIC SIGNAL IN CHINESE HAMSTER OVARY CELLS CHO-K1 UTILIZING INSULIN-INDEPENDENT MUTANTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 9, 1991, pages 3530-3534, XP002171752 1991 ISSN: 0027-8424	
A	WO 98 26063 A (MAIRA MARIO ; DROUIN JACQUES (CA); MONTREAL INST RECH CLINIQUES (CA) 18 June 1998 (1998-06-18)	
P, A	WO 00 77202 A (SMITHKLINE BEECHAM PLC) 21 December 2000 (2000-12-21) cited in the application	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6

Claims 1 (partially) and 6 refer to the use of an agonist of the polypeptides without giving a true technical characterization. Moreover no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 01/01211

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9404675 A	03-03-1994	AU 4950393 A	15-03-1994
WO 9826063 A	18-06-1998	CA 2192754 A	12-06-1998
		AU 5470598 A	03-07-1998
WO 0077202 A	21-12-2000	NONE	

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70254 A1

- (51) International Patent Classification⁷: **A61K 38/17**,
A61P 3/04, 3/10, 5/48, C07K 14/705
- (21) International Application Number: PCT/GB01/01211
- (22) International Filing Date: 19 March 2001 (19.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0006864.3 21 March 2000 (21.03.2000) GB
- (71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (72) Inventors; and
- (73) Inventors/Applicants (for US only): **CAIRNS, William, John** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **HOLDER, Julie, Caroline** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **PATEL, Lisa** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).
- (54) Agent: **CONNELL, Anthony, Christopher**; Corporate Intellectual Property, SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/70254 A1

(54) Title: USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

(57) Abstract: The use of NOT1 or NOT1 polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions.

USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

Field of the Invention

This invention relates to new uses for polynucleotides and polypeptides encoded by them, to their use in therapy and in identifying compounds which may be agonists which are potentially useful in therapy.

5

Summary of the Invention

In one aspect, the invention relates to new uses of the orphan nuclear receptor, NOT1 or its splice variant NOT1a polynucleotides and polypeptides. Such uses include the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, hereinafter referred to as "the Diseases", amongst others. In another aspect the invention relates to methods for identifying compounds which activate NOT1 or NOT1a polypeptides, for example agonists, using NOT1 or NOT1a materials, and treating conditions associated with NOT1 or NOT1a imbalance with the identified agonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NOT1 or NOT1a activity or levels.

15

Description of the Invention

In a first aspect, the present invention relates to the use of a compound selected from:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a compound which activates a NOT1 or NOT1a polypeptide; or
- (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,

20

for the manufacture of a medicament for treating:

- (i) obesity;
- (ii) insulin resistance;
- (iii) type 2 diabetes;
- (iv) impaired glucose tolerance;
- (v) cachexia; or
- (vi) liposarcoma.

25

Such NOT1 polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

30

Further polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

NOT1a polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include those comprising the amino acid of SEQ ID NO:4

Further NOT1a polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include the polypeptide of SEQ ID NO:4. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The NOT1 and NOT1a polypeptides relating to the present invention also include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

NOT1 and NOT1a polypeptides relating to the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to NOT1 or NOT1a polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID

NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 or SEQ ID NO:3 encoding the polypeptides of SEQ ID NO:2 and SEQ ID NO:4 respectively.

Further polynucleotides relating to the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:4, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:3 over the entire length of SEQ ID NO:1 or SEQ ID NO:3 respectively. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 as well as the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.

The invention also relates to polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of a human NOT1 cDNA is given in SEQ ID NO:1 (from Mages, H.W. et al. Mol. Endocrinol. 1994; 4(11): 1583-1591, EMBL: X75918). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 318 to 3115) encoding a polypeptide of 598 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The nucleotide sequence of the splice variant NOT1a is given in SEQ ID NO:3 (from Patent Application WO00/77202; SmithKline Beecham) and is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1368) encoding a polypeptide of 455 amino acids, the polypeptide of SEQ ID NO:4, representing a splice variant of NOT1. The nucleotide sequence encoding the polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:3 or it may be a

sequence other than the one contained in SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

The gene encoding the NOT1 polypeptide of SEQ ID NO:2 has been localised to human chromosome 2q22-2q23..

5 Preferred polypeptides and polynucleotides are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one NOT1 or NOT1a activity, which may include antigenic activity.

10 NOT1 and NOT1a polynucleotides may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Such polynucleotides can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When NOT1 or NOT1a polynucleotides are used for the recombinant production of NOT1 or NOT1a polypeptides, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence, or other fusion peptide portions. For example, a marker sequence which
20 facilitates purification of the fused polypeptide can be encoded, for example a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25 Recombinant NOT1 or NOT1a polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from NOT1 or NOT1a DNA constructs.

30 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for NOT1 or NOT1a polynucleotides. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate

transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect
5 cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK and HEK 293.

The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be
10 incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is
15 recovered.

NOT1 or NOT1a polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography
20 and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of
25 SEQ ID NO:1 or SEQ ID NO:3 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression or otherwise altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood,
30 urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled NOT1 or NOT1a nucleotide

sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242).

5 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising NOT1 or NOT1a nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known
10 and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the NOT1 gene by the methods described. In addition,
15 such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased level of polypeptide or mRNA. Decreased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can
20 be used to determine levels of a NOT1 or NOT1a protein in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:
(a) a NOT1 or NOT1a polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1 or
25 SEQ ID NO:3, or fragments thereof;
(b) a nucleotide sequence complementary to that of (a);
(c) a NOT1 or NOT1a polypeptide, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof; or
(d) an antibody to a NOT1 or NOT1a polypeptide, preferably to the polypeptide of SEQ ID NO:2
30 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, amongst others.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against NOT1 or NOT1a polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a NOT1 or NOT1a polypeptide, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

In a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate the function of NOT1 or NOT1a polypeptides. In general, agonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the

polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

5 The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Further, the screening methods may simply comprise the steps of mixing a
10 candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring NOT1 or NOT1a activity in the mixture, and comparing the NOT1 or NOT1a activity of the mixture to a standard.

NOT1 or NOT1a polynucleotides, polypeptides and antibodies to the polypeptide as hereinabove described may also be used to configure screening methods for detecting the effect
15 of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may enhance the production of polypeptide, for example agonists, from suitably manipulated cells or tissues.

20 The NOT1 or NOT1a polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated
25 with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists of NOT1 or NOT1a polypeptides which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

30 Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which enhance the production of such polypeptides, which comprises:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a recombinant cell expressing a NOT1 or NOT1a polypeptide;

(c) a cell membrane expressing a NOT1 or NOT1a polypeptide; or

(d) antibody to a NOT1 or NOT1a polypeptide;

which NOT1 or NOT1a polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:4.

5 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist of the NOT1 or NOT1a polypeptide, by:

10 (a) determining in the first instance the three-dimensional structure of the NOT1 or NOT1a polypeptide;

(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist;

(c) synthesising candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and

15 (d) testing whether the candidate compounds are indeed agonists.

It will be further appreciated that this will normally be an iterative process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia, or liposarcoma, related to an under-expression of, NOT1 or NOT1a polypeptide activity.

20 For treating abnormal conditions related to an under-expression of NOT1 or NOT1a polypeptides and their activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene
25 therapy may be employed to effect the endogenous production of NOT1 or NOT1a by the relevant cells in the subject. For example, a NOT1 or NOT1a polynucleotide may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a NOT1 or NOT1a polypeptide such that the packaging
30 cell now produces infectious viral particles containing the NOT1 or NOT1a gene. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the NOT1 or NOT1a polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another

approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a NOT1 or NOT1a polypeptide, such as the soluble
5 form of a NOT1 or NOT1a polypeptide, agonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
10 NOT1 or NOT1a polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be
15 used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a NOT1 or NOT1a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the
20 like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 $\mu\text{g/kg}$ of subject. Wide variations in the needed dosage, however, are to be
25 expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

NOT1 or NOT1a polypeptides used in treatment can also be generated endogenously in the
30 subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a NOT1 or NOT1a polynucleotide, such as a DNA or RNA, to encode a NOT1 or NOT1a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

“Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an
5 Fab or other immunoglobulin expression library.

“Isolated” means altered “by the hand of man” from the natural state. If an “isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the
10 coexisting materials of its natural state is “isolated”, as the term is employed herein.

“Polynucleotide” generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-
15 and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
20 “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as
25 oligonucleotides.

“Polypeptide” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

“Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain
30 amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

- 5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking,
- 10 cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for
- 15 instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).
- 20

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a

25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many

30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.

- 5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*,
10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity
15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410
20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

- 25 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)
Gap Penalty: 12
Gap Length Penalty: 4

- 30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the
5 default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical
to the reference sequence of SEQ ID NO:1 or SEQ ID NO:3, that is be 100% identical, or it may
include up to a certain integer number of nucleotide alterations as compared to the reference
sequence. Such alterations are selected from the group consisting of at least one nucleotide
10 deletion, substitution, including transition and transversion, or insertion, and wherein said
alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or
anywhere between those terminal positions, interspersed either individually among the
nucleotides in the reference sequence or in one or more contiguous groups within the reference
sequence. The number of nucleotide alterations is determined by multiplying the total number of
15 nucleotides in SEQ ID NO:1 or SEQ ID NO:3 by the numerical percent of the respective percent
identity(divided by 100) and subtracting that product from said total number of nucleotides in
SEQ ID NO:1 or SEQ ID NO:3, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ
20 ID NO:1 or SEQ ID NO:3, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90
for 90%, 0.95 for 95%, etc., and wherein any non-integer product of x_n and y is rounded down to
the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence
encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 may create nonsense, missense or
frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the
25 polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the
reference sequence of SEQ ID NO:2 or SEQ ID NO:4, that is be 100% identical, or it may
include up to a certain integer number of amino acid alterations as compared to the reference
sequence such that the % identity is less than 100%. Such alterations are selected from the group
30 consisting of at least one amino acid deletion, substitution, including conservative and non-
conservative substitution, or insertion, and wherein said alterations may occur at the amino- or
carboxy-terminal positions of the reference polypeptide sequence or anywhere between those
terminal positions, interspersed either individually among the amino acids in the reference
sequence or in one or more contiguous groups within the reference sequence. The number of

amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, or:

$$n_a \leq x_a - (x_a \cdot y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Examples

Example 1 - Analysis of NOT1 and NOT1a expression in human tissues

5

Generation of samples for TaqMan mRNA analysis: Human tissue or RNA was purchased (Biochain, San Leandro, CA; Invitrogen, Leek, The Netherlands; Clontech, Palo Alto, CA) or donated (Netherlands Brain Bank, Amsterdam, the Netherlands) and poly A+ RNA was prepared by the PolyATract method according to manufacturers instructions (Promega, USA). The poly

10 A+ RNA samples from 20 body tissues and 19 brain-regions from 4 individuals per tissue (two males/two females) were quantitated using OD260nm measurement or the RiboGreen fluorescent method (Molecular Probes, Oregon, USA) and 1ug of each RNA was reverse transcribed using random nonomers and Superscript II reverse transcriptase according to manufacturers instructions (Life Technologies). The cDNA prepared was diluted to produce up to 1,000

15 replicate 96-well plates using Biomek robotics (Beckman Coulter, High Wycombe, UK), so that each of the wells contained the cDNA produced from 1ng RNA for the appropriate tissue. The 96-well plates were stored at -80°C prior to use.

TaqMan PCR: This was performed following the procedure published by Sarau H.M. et al,

20 ("Identification, Molecular Cloning, Expression and Characterisation of a Cysteinyl Leukotriene Receptor", Molecular Pharmacology, 1999, 56, 657-663.) TaqMan quantitative PCR was conducted to measure either NOT-1 or NOT1a using replicate 96-well plates. A 20ul volume of a PCR master mix (containing 2.5ul TaqMan buffer, 6ul 25mM MgCl₂, 0.5ul of 10mM dATP, 0.5ul of 20mM dUTP, 0.5ul of 10mM dCTP, 0.5ul of 10mM dGTP, 0.25ul Uracil-N-glycosylase,

25 1ul of 10uM forward primer, 1ul of 10uM reverse primer, 0.5ul 5uM TaqMan probe, 0.125ul TaqGold [PE Biosystems], 6.625ul water) was added to each well using Biomek robotics (Beckman Coulter, High Wycombe, UK), and the plate capped using optical caps (PE Biosystems). The PCR reaction was carried out on an ABI7700 Sequence Detector (PE Biosystems) using the PCR parameters: 50°C for 2 minutes, 95°C for 10 minutes and 45 cycles

30 of 94°C for 15 seconds, 60°C for 1 minute, and the level of mRNA-derived cDNA in each sample was calculated from the TaqMan signal using plasmid/genomic DNA calibration standards included in each run. The level of genomic DNA contaminating the original RNA samples was shown to be negligible (<10 copies genomic DNA/ng RNA) by TaqMan measurement of genomic sequence for ten genes in replicate samples taken through the reverse transcription

procedure described with the omission of reverse transcriptase. Gene-specific reagents for NOT-1:

forward primer: 5'-CCGCCAGCAATAATTGACAA-3',

reverse primer: 5'-TTCCATTATCATTCCAGTTCCTTTG-3',

5 TaqMan probe: 5'-CACTTTACCTTTCTAAGACCTCCTCCCAAGCA-3';

and for NOT1a:

forward primer: 5'-TCCTTCGATTAGCATACAGAATA-3',

reverse primer: 5'-CCCGTGTCTCTCTGTGACCAT-3',

TaqMan probe: 5'-TCTGCCTTCTCCTGCATTGCTGCC-3'.

10

Results

The results are shown in Table 1. Analysis of expression of both NOT1 and NOT1a mRNA by TaqMan showed relatively widespread distribution. However, the expression levels found in adipose tissue were significantly higher than for those found in any other tissue. Levels of expression are scored from +++++ to -, with +++++ representing the highest expression levels. +/- indicates weakly detectable expression.

Table 1

		NOT1	NOT1a
20	Brain	++	+
	Pituitary	+++	++
	Heart	+	+/-
	Lung	+	+/-
	Liver	+	+
25	Foetal Liver	+	+/-
	Kidney	+	+
	Skeletal Muscle	++	++
	Stomach	+	+
	Intestine	+	+
30	Spleen	+	+
	Lymphocytes	++	++
	Macrophage	-	-
	Adipose	+++++	+++++
	Pancreas	+	+
35	Prostate	++	+

Placenta	+	+
Cartilage	+	+
Bone	-	-
Bone Marrow	+/-	+/-

5

Example 2 - Analysis of NOT1 expression in 3T3 cells

Insulin and dexamethasone induced differentiation of 3T3-L1 cells is an established in vitro model for adipogenesis. Levels of NOT1 mRNA were quantified in this model. The 3T3-L1 fibroblast cell line was obtained from the American Type Culture Collection. Cells were
 10 grown to confluence in Dulbeccos modified Eagles Medium containing 10% FCS. Differentiation was undertaken with in Dulbeccos modified Eagles Medium containing 10% FCS supplemented with 0.5mM isobutyl methyl xanthine, 0.25uM dexamethasone and insulin (5ug/ml) for 48 hours followed by Dulbeccos modified Eagles Medium containing 10% FCS supplemented with insulin (5ug/ml) for a further 48 hours. Cells were grown in Dulbeccos modified Eagles Medium
 15 containing 10% FCS for the remainder of the culture period.

On each day of experimentation the cell media was removed by aspiration and the cell monolayer extracted with 1ml of Trizol. RNA was prepared according to the manufacturer's instructions. Quantification of mRNA transcripts was carried out using the Taqman 5' nuclease assay as previously described (Wang T & Brown MJ (1999) Anal. Biochem. 269 p198-201).
 20 Total RNA was treated with DNaseI (Gibco BRL) and reverse transcribed using random hexamers (Stratagene) and Superscript II reverse transcriptase (Gibco BRL). Transcript cDNA levels were then measured using Taqman assay primers and fluorogenic probes as described in example 1. The results are shown in Table 2. In Table 2, T1 refers to day 1, T2 to day 2 etc. and the figures in the right hand column indicate relative levels of Not1 mRNA, the figure on day 1
 25 being 100%.

Table 2

T1	100
T2	139
T3	57
T4	2.8
T5	3.7
T6	0.9
T7	3.9
T8	8.7
T9	0.6
T10	n.d.
T11	3.4
T12	8.5

The results show that NOT1 expression is downregulated upon differentiation of 3T3-L1 cells, an established in vitro model for adipogenesis. This finding is consistent with NOT1 having a
5 function in maintaining the undifferentiated pre-adipocyte state.

SEQUENCE INFORMATION

SEQ ID NO:1

GCTCGCGCAGGGCTCCGCGGTCCCTTTTGCCCTGTCCAGCCGGCCGCTGTCCCTGCTCCCTCCCTCCGTGAGTGTCCGGG
TTCCCTTCGCCCAGCTCTCCCACCCCTACCCGACCCCGGCGCCCGGGCTCCCAGAGGGAACCTGCACCTTCGGCAGAGTTGA
5 ATGAATGAAGAGAGACGCGGAGAACTCCTAAGGAGGAGATTGGACAGGCTGGAACCTCCCATTTGCTTTTCTAAAAATCTTG
GAAACTTTGTCTTCATTGAATTACGACACTGTCCACCTTTAATTTCTCGAAAACGCTGTAACTCGGCTGAAGCCATG
CCTTGTGTTTCAGGCGCAGTATGGGTCTCGCCTCAAGGAGCCAGCCCCGCTTCTCAGAGCTACAGTTACCACTCTTCGGG
AGAATACAGCTCCGATTTCTTAACTCCAGAGTTTGTCAAGTTTAGCATGGACCTCACCAACACTGAAATCACTGCCACCA
CTTCTCTCCCCAGCTTCAGTACCTTTATGGACAACCTACAGCACAGGCTACGACGTCAAGCCACCTTGCTTGTACCAAATG
10 CCCCTGTCCGGACAGCAGTCTCCATTAAGGTAGAAGACATTAGATGCACAACCTACCAGCAACACAGCCACCTGCCCCC
CCAGTCTGAGGAGATGATGCCGCACTCCGGGTCGGTTTACTACAAGCCCTCTCGCCCCGACGCCACCACCCCGGGCT
TCCAGGTGCAGCACAGCCCCATGTGGGACGACCCGGGATCTCTCCACAACCTCCACCAGAACTACGTGGCCACTACGCAC
ATGATCGAGCAGAGGAAAACGCCAGTCTCCCGCTCTCCCTCTTCTCCTTTAAGCAATCGCCCCCTGGCACCCCGGTGTC
TAGTTGCCAGATGCGCTTCGACGGGCCCCGTCACGTCCCATGAACCCGGAGCCCGCGGCAGCCACCACGTGGTGGACG
15 GGCAGACCTTCGCTGTGCCCCAACCCCATTCGCAAGCCCGCTCCATGGGCTTCCCGGGCCTGCAGATCGGCCACGCGTCT
CAGTGTCTCGACACGCGAGTGCCCTCACCGCCGTCGCGGGGCTCCCCCTCCAACGAGGGGCTGTGCGCTGTGTGTGGGA
CAACCGGGCTGCCAACACTACGGCGTGCGCACCTGTGAGGGCTGCAAAGGCTTCTTTAAGCGCACAGTGCAAAAAATG
CAAATACGTGTGTTTAGCAAATAAAAACTGCCAGTGGACAAGCGTCGCCGGAATCGCTGTGAGTACTGCCGATTTCAG
AAGTGCCTGGCTGTTGGGATGGTCAAAGAAGTGGTTCGCACAGACAGTTTAAAGGCCGGAGAGGTGCTTTGCCCTCGAA
20 ACCGAAGAGCCCACAGGAGCCCTCTCCCCCTTCGCCCCCGGTGAGTCTGATCAGTGCCCTCGTCAGGGCCCATGTGCACT
CCAACCCGGCTATGACCAGCCTGGACTATTCCAGGTTCCAGGCGAACCCCTGACTATCAAATGAGTGGAGATGACACCCAG
CATATCCAGCAATTCTATGATCTCTGACTGGCTCCATGGAGATCATCCGGGGCTGGGCAGAGAAGATCCCTGGCTTCGC
AGACCTGCCCAAAGCCGACCAAGACCTGCTTTTGAATCAGCTTTCTTAGAACTGTTTGTCTTCGATTAGCATACAGGT
CCAACCCAGTGGAGGGTAAACTCATCTTTTGCAATGGGGTGGTCTTGACAGGTTGCAATGCGTTTCGTGGCTTTGGGGAA
25 TGGATTGATTCCATTGTTGAATTCTCCTCAAACCTGCAGAATATGAACATCGACATTTCTGCCTTCTCTGCATTGCTGC
CCTGGCTATGGTCACAGAGAGACACGGGCTCAAGGAACCCAAGAGAGTGGAAAGAACTGCAAAAACAAGATTGTAATTTGTC
TCAAAGACCACGTGACTTTCAACAATGGGGGTTGAACCGCCCCAATTATTTGTCCAACTGTTGGGAAGCTCCAGAA
CTTCGTACCCTTTGCACACAGGGGCTACAGCGCATTTTCTACCTGAAATTGGAAGACTTGGTGCCACCGCCAGCAATAAT
TGACAACTTTTCTGGACACTTTACCTTTCTAAGACCTCTCCCAAGCACTTCAAAGGAACTGGAATGATAATGGAAAC
30 TGTCAAGAGGGGGCAAGTCACATGGGCAGAGATAGCCGTGTGAGCAGTCTCAGCTCAAGCTGCCCCCATTTCTGTAACC
CTCCTAGCCCCCTTGATCCCTAAAGAAAACAAACAAACAAACAACTGTTGCTATTTCTTAACCTGCAGGCAGAACCT
GAAAGGGCATTTTGGCTCCGGGGCATCCTGGATTTAGAACATGGACTACACACAATACAGTGGTATAAACTTTTATTCT
CAGTTTAAAAATCAGTTTGTGTTTCAAGAAAGATTGCTATAAGGTATAATGGGAAATGTTTGGCCATGCTTGGTGTGTT
GCAGTTCAGACAAATGTAACACACACACATACACACACACACAGAGACACATCTTAAGGGGACCCACAAGTA
35 TTGCCCTTTAACAAGACTTCAAAGTTTTCTGCTGTAAAGAAAGCTGTAATATATAGTAAACTAAATGTTGCGTGGGTGG
CATGAGTTGAAGAAGGCAAAGCTTGTAATTTACCCAATGCAGTTTGGCTTTTTAAATATTTTGTGCCTATTATGAA
TAAATATTACAAATCTAAAAGATAAGTGTGTTTGCAAAAAAAGAAATAAATACATAAAAAAGGGACAAGCATGTTG
ATTCTAGGTTGAAAATGTTATAGGCACTTGCTACTTCAGTAATGTCTATATTATATAAATAGTATTTAGACACTATGTA
GTCTGTTAGATTTTATAAAGATTGGTAGTTATCTGAGCTTAAACATTTCTCAATTGTAAATAGGTGGGCACAAGTATT
40 ACACATCAGAAAATCCTGACAAAAGGGACACATAGTGTGTTGTAACACCGTCCAACATTCCTTGTGTGTAAGTGTGTATG
TACCGTTGATGTGATAAAAAGAAAGTTTATATCTTGATTATTTTGTGTCTAAAGCTAAACAAACTTGCATGCAGCAG

CTTTTGAAGTTTCCAGAGTGCTTATAATATACATAACTCCCTGGAAATAACTGAGCACTTTGAATTTTTTTTATGTCTA
AAATTGTGAGTTAATTTATTATTTTGTGTTGAGTAAGAATTTTAATATTGCCATATTCTGTAGTATTTTCTTTGTATATT
TCTAGTATGGCACATGATATGAGTCACTGCCTTTTTTCTATGGTGTATGACAGTTAGAGATGCTGATTTTTTTTCTGAT
AAATTCTTTCTTTGAGAAAGACAATTTTAATGTTTACAACAATAAACCATGTAAATGAAAAAAAAA

5

SEQ ID NO:2

MPCVQAQYGSSPQGASPASQSYSHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLSFSSTFMD
NYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYKPSPPPTP
TTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSCQMRFD
10 GPLHVPMPNEPAGSHHVVDGQTFVNPPIRKPA SMGFPGLQIGHASQLLDTQVPSPPSRGSPSNE
GLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNKYVCLANKNCPVDKRRRNRCQYCRFQKCLA
VGMVKEVVRTDSLKGRRRLPSKPKSPQEPSPPSPVSLISALVRAHVDSNPAMTSLDYSRFQAN
PDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFLVRLAYRS
NPVEGKLIFCNGVVLHRLQCVRGFGWIDSIVEFSSNLQNMNIDISAFSCIAALAMVTERHGLKE
15 PKRVEELQNKIVNCLKDHVTFNNGGLNRPNYLSKLLGKLPELRTLCTQGLQRI FYLKLEDLVPPP
AIIIDKFLDLTLPF

SEQ ID NO:3

ATGCCTTGTTGTTTCAGGCGCAGTATGGGTCTCGCCTCAAGGAGCCAGCCCCGCTTCTCAGAGCTA
20 CAGTTACCACTCTTCGGGAGAATACAGCTCCGATTCTTAACTCCAGAGTTTGTCAAGTTTAGCA
TGGACCTCACCAACACTGAAATCACTGCCACCACCTTCTCTCCCCAGCTTCAGTACCTTTATGGAC
AACTACAGCACAGGCTACGACGTCAAGCCACCTTGCTTGTACCAAATGCCCCGTGCCGGACAGCA
GTCCTCCATTAAGGTAGAAGACATTAGATGCACAACTACCAGCAACACAGCCACCTGCCCCCCC
AGTCTGAGGAGATGATGCCGCACTCCGGGTCTGGTTTACTACAAGCCCTCCTCGCCCCCGACGCCC
25 ACCACCCCGGGCTTCCAGGTGCAGCACAGCCCCATGTGGGACGACCCGGGATCTCTCCACAACTT
CCACCAGAACTACGTGGCCACTACGCACATGATCGAGCAGAGGAAAACGCCAGTCTCCCGCCTCT
CCCTCTTCTCCTTTAAGCAATCGCCCCCTGGCACCCTGGTGTCTAGTTGCCAGATGCGCTTCGAC
GGGCCCCCTGCACGTCCCCATGAACCCGGAGCCCGCCGGCAGCCACCACGTGGTGGACGGGCAGAC
CTTCGCTGTGCCCCAACCCCATTCGCAAGCCCGGTCCATGGGCTTCCCGGGCCTGCAGATCGGCC
30 ACGCGTCTCAGCTGCTCGACACGCAGGTGCCCTCACCGCCGTGCGGGGGCTCCCCCTCCAACGAG
GGGCTGTGCGCTGTGTGTGGGGACAACGCGGCCTGCCAACACTACGGCGTGCGCACCTGTGAGGG
CTGCAAAGGCTTCTTTAAGCGCACAGTGCAAAAAATGCAAAATACGTGTGTTTAGCAAATAAAA
ACTGCCCAGTGGACAAGCGTCGCCGGAATCGCTGTGAGTACTGCCGATTTAGAAAGTGCCTGGCT
GTTGGGATGGTCAAAGAAGTGGTTCGCACAGACAGTTTAAAAGGCCGGAGAGGTGCTTTGCCCTC
35 GAAACCGAAGAGCCACAGGAGCCCTCTCCCCCTTCGCCCCCGGTGAGTCTGATCAGTGCCCTCG

TCAGGGCCCATGTCGACTCCAACCCGGCTATGACCAGCCTGGACTATTCCAGGTTCCAGGCGAAC
CCTGACTATCAAATGAGTGGAGATGACACCCAGCATATCCAGCAATTCTATGATCTCCTGACTGG
CTCCATGGAGATCATCCGGGGCTGGGCAGAGAAGATCCCTGGCTTCGCAGACCTGCCCAAAGCCG
ACCAAGACCTGCTTTTTGAATCAGCTTTCTTAGAACTGTTTGTCTTCGATTAGCATAACAGAATA
5 TGAACATCGACATTTCTGCCTTCTCCTGCATTGCTGCCCTGGCTATGGTCACAGAGAGACACGGG
CTCAAGGAACCCAAGAGAGTGAAGAAGTCAAAAACAAGATTGTAAATTGTCTCAAAGACCACGT
GACTTTCAACAATGGGGGGTTGAACCGCCCCAATTATTTGTCCAACTGTTGGGGAAGCTCCCAG
AACTTCGTACCCTTTGCACACAGGGGCTACAGCGCATTCTTCTACCTGAAATTGGAAGACTTGGTG
CCACCGCCAGCAATAATTGACAACTTTTCCTGGACACTTTACCTTTCTAA

10

SEQ ID NO:4

MPCVQAQYGSSPQGASPASQSYSYHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLPSTFMD
NYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYKPPSSPPTP
TTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSQMRFD
15 GPLHVPMNPEPAGSHHVVDGQTFVAVPNPIRKPASMGFPGLQIGHASQLLDTQVPSPPSRGSPTSNE
GLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQKCLA
VGMVKEVVRTDSLKGRRGRLPSKPKSPQEPSPPSPVSLISALVRAHVDSNPAMTSLDYSRFQAN
PDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLRLAYRI.

Claims

1. The use of a compound selected from:
 - (a) a NOT1 or NOT1a polypeptide;
 - (b) a compound which activates a NOT1 or NOT1a polypeptide; or
 - (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,for the manufacture of a medicament for treating:
 - (i) obesity;
 - (ii) insulin resistance;
 - (iii) type 2 diabetes;
 - (iv) impaired glucose tolerance;
 - (v) cachexia; or
 - (vi) liposarcoma.
2. The use according to claim 1 wherein the medicament is used to treat obesity.
3. The use according to claim 1 wherein the medicament is used in the treatment of insulin resistance.
4. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 95% identity to the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
5. The use according to claim 4 wherein the isolated polypeptide is the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
6. The use according to claim 1 wherein the medicament comprises a compound which activates a NOT or NOT1a polypeptide.
7. The use according to claim 1 wherein the medicament comprises a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
8. The use according to claim 7 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
9. The use according to claim 7 or 8 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01211

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61P3/04 A61P3/10 A61P5/48 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)	
A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NURR1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295 ----- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

11 July 2001

Date of mailing of the international search report

27/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Blanco Urgoiti, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01211

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARUYAMA K ET AL: "THE NGFI-B SUBFAMILY OF THE NUCLEAR RECEPTOR SUPERFAMILY (REVIEW)" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,,GR, vol. 12, no. 6, 23 March 1998 (1998-03-23), pages 1237-1243, XP000946431 ISSN: 1019-6439	
A	ISHIHARA NORIKO ET AL: "Signal transduction pathways leading to the NOR-1 gene induction in MCF-7 breast cancer cells." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1047 XP002171751 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638	
A	MAMOUNAS M ET AL: "ANALYSIS OF THE GENES INVOLVED IN THE INSULIN TRANSMEMBRANE MITOGENIC SIGNAL IN CHINESE HAMSTER OVARY CELLS CHO-K1 UTILIZING INSULIN-INDEPENDENT MUTANTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 9, 1991, pages 3530-3534, XP002171752 1991 ISSN: 0027-8424	
A	WO 98 26063 A (MAIRA MARIO ;DROUIN JACQUES (CA); MONTREAL INST RECH CLINIQUES (CA) 18 June 1998 (1998-06-18)	
P,A	WO 00 77202 A (SMITHKLINE BEECHAM PLC) 21 December 2000 (2000-12-21) cited in the application	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6

Claims 1 (partially) and 6 refer to the use of an agonist of the polypeptides without giving a true technical characterization. Moreover no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 01/01211

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9404675 A	03-03-1994	AU 4950393 A	15-03-1994
WO 9826063 A	18-06-1998	CA 2192754 A	12-06-1998
		AU 5470598 A	03-07-1998
WO 0077202 A	21-12-2000	NONE	